(Q43224194)

English

Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination

scientific article published in December 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

immunosuppression

1 reference

based on heuristic

inferred from title

author name string

A Cataneo-Dávila

1

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

J Zúñiga-Varga

2

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

R Correa-Rotter

3

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

J Alberú

4

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

language of work or name

0 references

publication date

1 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Transplantation Proceedings

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

4138-4146

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Strategies to improve long-term outcomes after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Transplant: immunology and treatment of rejection

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Reduction in calcineurin inhibitor exposure and maintenance of effective immunosuppression: clinical experience with everolimus (Certican).

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Banff 07 classification of renal allograft pathology: updates and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Targeting mTOR signaling for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Inhibitors of the mammalian target of rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Early clinical experience with a novel rapamycin derivative

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Proteinuria: its clinical importance and role in progressive renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Conversion from cyclosporine to sirolimus in stable renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Afferent and efferent arteriolar vasoconstriction to angiotensin II and norepinephrine involves release of Ca2+ from intracellular stores

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Combination therapy with sirolimus and mycophenolate mofetil: effects on the kidney and on transforming growth factor-beta1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Conversion to everolimus in maintenance patients--current clinical strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2009.08.065

7 January 2021

Identifiers

10.1016/J.TRANSPROCEED.2009.08.065

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43224194&oldid=1984161927"